Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
HQ Australia · Asia-Pacific
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products not yet catalogued.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Sep 2026: Annalise.ai's owner Harrison.ai was reported to have made an undisclosed number of Australian roles redundant after an April 2026 consultation, while reorganising staff around AI agents; its government investor said it was aware of the changes.
No data breaches, cyber incidents or regulator actions involving Annalise.ai or Harrison.ai found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
No product recalls, safety notices or warning letters involving Annalise.ai found in HSH's search of the last 24 months. Mar 2026: Harrison.ai received FDA 510(k) clearance for acute infarct triage on non-contrast CT brain.
No contract terminations, disputes or troubled implementations involving Annalise.ai found in HSH's search of the last 24 months.
No competitors linked yet.